This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
by Zacks Equity Research
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
NVSNegative Net Change ALKSNegative Net Change INCYNegative Net Change SRPTPositive Net Change
biotechnology pharmaceuticals
Enphase Energy (ENPH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ENPHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
by Zacks Equity Research
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
ALKSNegative Net Change SRPTPositive Net Change SGENPositive Net Change NEXINo Net Change
biotechnology biotechs pharmaceuticals
After Golden Cross, Bassett Furniture (BSET)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BSETNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: ICPT's Study Data, NVAX Vaccine Gets EUA, VERU Up on Data
by Zacks Equity Research
Regulatory and other updates from Intercept (ICPT) and VERU are a few key highlights from the biotech sector during the past week.
VRTXPositive Net Change NVAXPositive Net Change ICPTPositive Net Change VERUPositive Net Change
biotechnology biotechs
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
by Zacks Equity Research
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
ALKSNegative Net Change PSTIPositive Net Change SRPTPositive Net Change SGENPositive Net Change
biotechnology biotechs pharmaceuticals
The Overlooked Difference in June's Inflation Report
by Bryan Hayes
Today's reaction to a high CPI print is the opposite of what we saw last month.
VRTXPositive Net Change IBBPositive Net Change
biotechnology biotechs earnings gene-editing genetic-testing investing large-cap medical tech-stocks
Seattle Genetics (SGEN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SGENPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
by Zacks Equity Research
Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology pharmaceuticals
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
CCBG, IMCR and FSTX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2022.
CCBGNegative Net Change IMCRNegative Net Change
biotechnology pharmaceuticals
Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.
NVSNegative Net Change LLYPositive Net Change ALKSNegative Net Change INCYNegative Net Change
biotechnology biotechs pharmaceuticals
Company News for Jul 8, 2022
by Zacks Equity Research
Companies In The News Are: GME, MRNA, LCID, SLP.
MRNANegative Net Change GMEPositive Net Change SLPNo Net Change LCIDPositive Net Change
auto-tires-trucks biotechnology computers retail
Pharma & Biotech ETFs at One-Month High: Here's Why
by Sanghamitra Saha
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
BBCPositive Net Change PJPPositive Net Change XPHNegative Net Change PBEPositive Net Change IEIHPositive Net Change GNOMNegative Net Change IBBQPositive Net Change
biotechnology etfs pharmaceuticals
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
by Zacks Equity Research
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
BMYPositive Net Change GERNNegative Net Change EXELPositive Net Change SESNPositive Net Change
biotechnology pharmaceuticals
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs pharmaceuticals
Virco Manufacturing Corporation (VIRC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VIRCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
by Zacks Equity Research
FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.
REGNNegative Net Change SNYPositive Net Change BAYRYNegative Net Change SESNPositive Net Change
biotechnology biotechs pharmaceuticals
This Small-Cap Innovator is Flying High
by Bryan Hayes
We may be turning the page to a new chapter where small-cap stocks re-establish their supremacy.
biotechnology biotechs earnings investing medical
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
by Zacks Equity Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
GILDNegative Net Change EPZMPositive Net Change IPSEYNo Net Change KZRPositive Net Change STRONegative Net Change
biotechnology pharmaceuticals
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
by Zacks Equity Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
GSKPositive Net Change GERNNegative Net Change GILDNegative Net Change SESNPositive Net Change
biotechnology biotechs pharmaceuticals
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
by Zacks Equity Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
GSKPositive Net Change GERNNegative Net Change ALKSNegative Net Change GILDNegative Net Change
biotechnology pharmaceuticals
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
BMYPositive Net Change GERNNegative Net Change ALKSNegative Net Change GILDNegative Net Change
biotechnology pharmaceuticals
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, UFCS, CWCO, HURN and FCN.
FCNPositive Net Change HURNPositive Net Change UFCSNegative Net Change CWCONegative Net Change IMCRNegative Net Change
biotechnology business-services insurance utilities
Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More
by Zacks Equity Research
Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.
MRNANegative Net Change BGNEPositive Net Change RYTMPositive Net Change ACERNo Net Change
biotechnology biotechs pharmaceuticals
Best Momentum Stocks to Buy for June 21st
by Zacks Equity Research
IMO, PAG and UTHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 21, 2022.
PAGNegative Net Change UTHRPositive Net Change IMOPositive Net Change
biotechnology medical oil-energy retail